Monoclonal antibodies are not recommended for Long COVID or Post COVID Complications.
All monoclonal antibodies in market (Indevimab Casirivimab, Sotrovimab etc) are approved for non hospitalised patients with active COVID with high risk factors.
HENCE Any therapeutic misadventure is not recommended.
Answered2022-01-07 15:22:19
Let others know if this answer was helpful